DAX-0,55 % EUR/USD+0,16 % Gold+0,55 % Öl (Brent)-2,03 %

Myriad Genetics erhält Patent für Krebsgen - 500 Beiträge pro Seite


WKN: 897518 | Symbol: MYGN
20,565
08:03:41
Frankfurt
-2,16 %
-0,455 EUR

Beitrag schreiben

Begriffe und/oder Benutzer

 

Myriad Genetics gab heute bekannt, dass es für das p10-Gen ein Patent erhalten hat. Das Gen könnte die Basis für die Herstellung von Medikamenten gegen viele bekannte Krebsarten bilden. Es gehört einer kleinen Gruppe sehr bedeutender Gene an, bei denen festgestellt wurde, dass sie bei einem hohen Prozentsatz von Krebsarten mutiert sind. Die Identifikation von Mutationen im p10-Gen könnte insbesondere bei der Feststellung von Empfänglichkeiten mancher Menschen für gewisse Krebsformen hilfreich sein.


Myriad Genetics Awarded US Patent on p10 Tumor Suppressor Gene

p10 Gene Involved in Most Common Cancers

SALT LAKE CITY, May 23 /PRNewswire/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) announced today that it has been awarded patent number 6,060,301 by the U.S. Patent and Trademark Office. The patent covers the p10 gene, which may provide the basis for the development of products to diagnose and treat many common cancers.

The p10 gene is a member of a small family of very important tumor suppressor genes that are mutated in a large percentage of cancers. Mutations in the p10 gene have been found in human cancers such as melanoma, leukemia, lymphoma and prostate cancer, colon cancer, breast cancer, kidney cancer, pancreatic cancer, bladder cancer, stomach cancer, ovarian cancer, uterine cancer and testicular cancer.

"Myriad continues to build an extremely strong intellectual property position through the award of patents on full length genes with known function and disease association intact," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "The Company believes that its patents are the strongest form of patent protection available for genomic discoveries."

The identification of mutations in the p10 gene may provide the basis of molecular diagnostic tests for predisposition to the various cancers. Moreover, the gene may become the basis for development of therapeutics to treat cancers of many types. Therapeutic approaches covered under this patent include gene therapy, protein replacement, protein mimetics and small molecule drugs.

Myriad Genetics, Inc. is an emerging biopharmaceutical company focused on the development of therapeutic and diagnostic products that are based on the use of genomic and proteomic technologies. The Company has established two wholly owned subsidiaries -- Myriad Pharmaceuticals, Inc., which develops and intends to market therapeutic compounds, and Myriad Genetic Laboratories, Inc., which develops and markets proprietary molecular diagnostic services and has introduced products in the fields of predictive medicine and personalized medicine. The Company has established strategic alliances with Bayer, Eli Lilly, Hitachi, Monsanto, Novartis, Roche, Schering AG and Schering-Plough.


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.